Use of aldosterone blockade to improve cardiac function in obesity

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000655246

Acronym

OB02

Enrollment

120

Registered

2009-08-04

Start date

2009-08-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Obesity is a risk factor for the development of heart failure. Many apparently well obese subjects have cardiac dysfunction that is detectable with specialized techniques, but which may contribute to the development of heart failure. There are several potential causes for this problem, but fibrosis (scarring) of the heart may be an important one. In this study, we plan to identify whether this can be treated with the aldosterone blocker, spironolactone.

Interventions

Spironolactone 25mg Oral tablets, once a day for a total of 26 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

Obesity: Body mass index (BMI) > 30

Exclusion criteria

Diabetes, cardiovascular disease or other chronic disease

Outcome results